Skip to main content

Table 7 Summary of prescribed medicines for management of skin rash

From: A retrospective study on the incidence, management and risk factors of skin rash in patients with advanced prostate cancer in Japan

 

nmCRPC

mCRPC

mCNPC

N = 356

N = 182

N = 131

Types of skin rash treatment, n (%)

 Oral antihistamine1

104 (29.21)

42 (23.08%)

41(31.30%)

 Systemic corticosteroid1

184 (51.69%)

122 (67.03%)

64 (48.85%)

 Topical corticosteroid

211 (59.27%)

76 (41.76%)

78 (59.54%)

Duration of skin rash treatment (Day)

 Oral antihistamine1

104

42

41

  Mean (SD)

101.29 (180.55)

101.12 (153.46)

158.37 (222.60)

  Median (Min:Max)

28 (1:1169)

30 (1:613)

40 (1:872)

  IQR (Min:Max)

98.5 (8:106.5)

100 (12:112)

167 (14:181)

 Systemic corticosteroid1

184

122

64

  Mean (SD)

167.42 (244.89)

119.56 (159.30)

141.05 (242.61)

  Median (Min:Max)

63.5 (1:1430)

59.5 (1:753)

51.5 (1:1333)

  IQR (Min:Max)

189 (21:210)

129 (24:153)

131.5 (19:150.5)

 Topical corticosteroid

211

76

78

  Mean

81.12 (149.55)

85.14 (159.90)

82.22 (160.95)

  Median

28 (28:1350)

28 (28:1223)

28 (28: 1,131)

  IQR

42 (28:70)

48.5 (28:76.5)

8 (28:36)

  1. N number of patients in a skin rash specific group, n Number of patients without missing value in a specific group, IQR Interquartile range, Max Maximum, mCNPC Metastatic castration-naïve prostate cancer, mCRPC Metastatic castration-resistant prostate cancer, Min Minimum, nmCRPC Non-metastatic castration-resistant prostate cancer, SD Standard deviation
  2. 1Including combination of systemic antihistamine and corticosteroid